Free tool
FAERS Monitor: Ninlaro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208462 or its brand name (Ninlaro, Ixazomib Citrate). Reports on generic versions are filed under their own applications.
Reports
28,726
Serious
21,353
74% of reports
Hospitalization
8,767
Death reported
5,294
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- plasma cell myeloma3,689
- death3,317
- diarrhoea3,163
- off label use2,976
- pneumonia1,937
- fatigue1,921
- nausea1,847
- neuropathy peripheral1,454
- vomiting1,110
- rash1,089
- thrombocytopenia1,050
- platelet count decreased1,008
- constipation968
- asthenia917
- product dose omission issue802
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 63 |
| 2016 | 1,879 |
| 2017 | 2,393 |
| 2018 | 3,382 |
| 2019 | 4,438 |
| 2020 | 4,066 |
| 2021 | 4,533 |
| 2022 | 2,966 |
| 2023 | 1,976 |
| 2024 | 1,630 |
| 2025 | 1,042 |
| 2026 | 354 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,025,433 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| plasma cell myelomaSignal | 3,689 | 76.3 | 74.0 | 248,797 |
| neuropathy peripheralSignal | 1,454 | 11.3 | 10.8 | 13,564 |
| platelet count decreasedSignal | 1,008 | 7.0 | 6.6 | 5,137 |
| thrombocytopeniaSignal | 1,050 | 6.9 | 6.5 | 5,301 |
| pneumoniaSignal | 1,937 | 4.4 | 4.2 | 5,136 |
| diarrhoeaSignal | 3,163 | 3.6 | 3.5 | 6,096 |
| constipationSignal | 968 | 3.3 | 3.1 | 1,523 |
| deathSignal | 3,317 | 2.8 | 2.7 | 4,063 |
| off label useSignal | 2,976 | 2.5 | 2.4 | 2,767 |
| product dose omission issue | 802 | 2.0 | 1.9 | 404 |
| rash | 1,089 | 1.8 | 1.7 | 418 |
| fatigue | 1,921 | 1.8 | 1.7 | 719 |
| asthenia | 917 | 1.8 | 1.7 | 322 |
| vomiting | 1,110 | 1.7 | 1.6 | 348 |
| nausea | 1,847 | 1.7 | 1.6 | 564 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.